Multiple Biotech Companies to Present Oncology Data at AACR 2025 Meeting

Incyte to Present Early Data on Oncology Portfolio at 2025 AACR Annual Meeting Incyte, a global biopharmaceutical company, will present early data from its oncology portfolio at the American Association for Cancer Research (AACR) annual meeting from April 25 to 30, 2025, in Chicago. The presentations focus on advancing treatments for myelodysplastic syndromes (MDS), ovarian cancer, and other solid tumors. Key Projects and Findings: INCB177054: This novel, potent, and orally bioavailable dual inhibitor of DGKα/ζ has shown promising results in enhancing T cell function and demonstrating strong antitumor activity. The data will be presented on April 28 during the "Novel Antitumor Agents" session (Abstract 3789). INCA33890: Compared to pembrolizumab, INCA33890, a bispecific antibody targeting PD-1 and TGFβR2, enhances CD8+ T cell effector function through single-cell RNA sequencing. This research will be displayed as a poster on April 29 during the "Immunometabolism and Cancer Immunoadaptation" session (Abstract 4861). INCA33890 also shows enhanced immune responses in ovarian cancer models, which will be discussed in a separate poster presentation on April 29 (Abstract 6074). Additional studies on how INCA33890 improves human T cell effector function in vitro and ex vivo will be shown on April 29 (Abstract 6071). INCB057643: Acting as a BET protein inhibitor, INCB057643 has demonstrated improvements in bone marrow function and increased erythropoiesis in MDS patients. These findings will be shared on April 30 during the "Molecular Genetics and Epigenetics of Cancer" session (Abstract 7188). Another study highlights INCB057643’s role in regulating myeloid cells and reshaping the immunosuppressive tumor microenvironment in bone marrow fibrosis (Abstract 7184). Cyclin E1 Expression in Ovarian Cancer: Researchers will also discuss the association between Cyclin E1 expression and genome instability in ovarian cancer, providing further insights into this complex disease (Abstract 2846). Incyte's President and Head of Research and Development, Pablo J. Cagnoni, Ph.D., emphasized that the data presented at AACR will guide future research directions and clinical trials. "These latest data represent a significant step forward in our mission to transform the treatment landscape for cancer and MDS patients," he stated. Talus Bio Showcases Innovative Transcription Factor Targeting Platform at 2025 AACR Talus Bio, a Seattle-based biotech company, will present preclinical data on its novel platform for targeting transcription factors at the AACR 2025 Annual Meeting. The platform aims to address previously "undruggable" transcription factors, which have been challenging to target with traditional small molecule drugs. Key Highlights: Poster 4036: "Selective Inhibition of Brachyury Transcription Factor in Chondrosarcoma and Non-Small Cell Lung Cancer (NSCLC)" by Gaëlle Mercenne demonstrates that TAL61, a covalent small molecule, effectively regulates Brachyury activity in patient-derived xenograft (PDX) models of chondrosarcoma. Poster 6991: "Transcriptional Inhibition of AR and ARv7 as a Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)" by Brian McEllin reveals that targeting NONO to disrupt AR and ARv7 transcription offers a new approach for treating mCRPC. Poster 4496: "Artificial Intelligence-Guided Discovery of Small Molecule Inhibitors for Previously 'Undruggable' Transcription Factors" by Alex Federation outlines how Talus Bio's regulome sequencing platform discovers and optimizes small molecule inhibitors of transcription factors. The platform analyzes over 10,000 regulomes per month, identifying potential cancer targets. Talus Bio CEO and co-founder, Alex Federation, Ph.D., highlighted the platform's ability to analyze millions of protein-compound interactions and its validation of multiple transcription factor targets. "Our progress in two complex tumor areas showcases the potential of our platform to bring transformative therapies to patients with unmet needs," he said. Industry experts view Talus Bio’s advancements as a significant breakthrough, particularly in addressing undruggable targets. Founded in 2020, Talus Bio is committed to developing innovative therapies for difficult-to-treat cancers. The company's expertise in proteomics, chemistry, and machine learning positions it as a leader in the field. Repare Therapeutics to Unveil New Precision Oncology Data at 2025 AACR Repare Therapeutics, a clinical-stage precision oncology company, will present six abstracts at the 2025 AACR Annual Meeting in Chicago. The company focuses on discovering and developing novel high-selectivity cancer therapies using its proprietary SNIPRx® platform, which leverages CRISPR gene editing for synthetic lethality screening. Mini Oral Presentations: Alison M. Schram, MD: "Efficacy and Safety of the Combination of PKMYT1 Inhibitor Lunresertib and ATR Inhibitor Camonsertib in Patients with Ovarian and Endometrial Cancers: Phase I MYTHIC Study." This report, presented on April 29, highlights the potential of combining these inhibitors in treating ovarian and endometrial cancers. John M. Maris, MD: "Activity of PLK4 Inhibitor RP-1664 in Preclinical Neuroblastoma Models, Including Its Capacity to Drive Centrosome Loss and Induce Tumor Regression Alone." On April 27, this presentation explores how RP-1664 can inhibit neuroblastoma growth by affecting centrosome regulation. Posters: Michal Zimmermann, PhD: "Dual Mechanisms of Sensitivity to PLK4 Inhibition in Neuroblastoma Models." Presented on April 27, this poster discusses the specific mechanisms behind RP-1664's efficacy in neuroblastoma (Abstract 365). Anne Roulston, PhD: "Efficient and Selective PLK4 Inhibitor RP-1664 Induces Tumor Regression in Xenograft Models of Solid Tumors with Amplified TRIM37 Expression." On April 28, the poster examines the effectiveness of RP-1664 in various solid tumors (Abstract 1734). Isabel Soria-Bretones, PhD: "Copy Number Variations of the TRIM37 Gene and Development of FISH Assays for Their Detection in Pan-Cancer Analysis." This poster, presented on April 27, delves into TRIM37 gene variations and their detection methods (Abstract 717). Sung Joo Jang, PhD: "Targeting CCNE1 Amplification in Gastric Cancer." On April 30, this poster explores the role of CCNE1 amplification in gastric cancer and the possibilities for targeted therapy (Abstract 6942). These presentations showcase Repare Therapeutics' progress in developing precision oncology drugs, particularly the promising results of Lunresertib and Camonsertib in combination and RP-1664 in various cancer models. The company's unique approach, focusing on synthetic lethality and gene-specific targets, underscores its commitment to delivering highly targeted cancer treatments. NextPoint Therapeutics to Highlight B7-H7 Targeted Therapies at 2025 AACR NextPoint Therapeutics, a clinical-stage biotechnology company, will present groundbreaking preclinical data on its lead candidate, NPX125, an antibody-drug conjugate (ADC) targeting B7-H7, at the AACR 2025 Annual Meeting. NPX125 utilizes the company's proprietary linker technology combined with a validated topoisomerase 1 inhibitor payload, designed for a high drug-to-antibody ratio (DAR8). Key Abstract and Poster: Poster 7336: "B7-H7 as a Novel ADC Target for Solid Tumors: Demonstrating Potent Activity Across Multiple Payload-Linker Architectures." This poster, presented on April 30 from 9:00 AM to 12:00 PM, showcases NPX125's superior internalization kinetics, robust cytotoxicity, and strong antitumor activity in different B7-H7 expressing tumor models. Chief Scientific Officer, Tatiana Novobrantseva, Ph.D., noted that NPX125 outperformed other B7-H7 targeting ADCs in preclinical tests. "Our data confirms the significant potential of B7-H7 as a target for cancer therapy, especially considering the broad expression of the antigen across various solid tumors," she said. NextPoint Therapeutics is advancing its B7-H7 axis-focused projects, including ADCs, T cell activators, and multifunctional checkpoint inhibitors. The company's innovation lies in combining basic science with clinical biomarkers to identify the most suitable patient populations, thereby enhancing therapeutic outcomes. Founded in 2018, NextPoint Therapeutics is headquartered in Cambridge, Massachusetts. The company's focus on B7-H7-targeted therapies and its cutting-edge linker technology have garnered positive attention from industry experts, who see the potential for NextPoint to significantly impact the ADC landscape and offer new hope to patients with hard-to-treat cancers. Obsidian Therapeutics to Present CytoDRiVE Technology Advancements at 2025 AACR Obsidian Therapeutics, a clinical-stage biotech company, will present several reports at the 2025 AACR Annual Meeting, highlighting advancements in its cytoDRiVE® platform for engineering and gene therapies. The company's presentations include three posters and updates on the multi-center Agni-01 trial design (NCT06060613). Key Presentations: Mini Oral Presentation LB025: "cytoDRiVE Platform for Spatiotemporal Control of Membrane-Bound IL-12 in Allogeneic Models Enhances Therapeutic Potential." This report, presented on April 27, showcases how the platform precisely controls IL-12 expression to enhance tumor control rates while maintaining safety. Mini Oral Presentation LB359: "Multimodal Phenotypic Analysis: OBX-115 TILs Show Reduced Exhaustion and Enhanced CD8+ and Stem Memory T Cell Content in NSCLC." On April 28, the presentation compares OBX-115 TILs with traditional TILs, demonstrating reduced exhaustion and enriched CD8+ T cell content. Posters: Abstract 365: "Dual Mechanisms of Sensitivity to PLK4 Inhibition in Neuroblastoma." Presenting data on how PLK4 inhibition affects neuroblastoma cells, this poster provides insights into the specific mechanisms involved. Abstract 1734: "Efficient and Selective PLK4 Inhibitor RP-1664 Induces Tumor Regression in TRIM37-Amp Solid Tumor Xenograft Models." This poster, also presented on April 28, explores the efficacy of PLK4 inhibition in solid tumors with amplified TRIM37 expression. Abstract 717: "Pan-Cancer Analysis of TRIM37 Copy Number Variations and Development of a FISH Tool for Screening." On April 27, the poster details the analysis of TRIM37 CNVs and the development of a FISH assay for patient screening. Abstract 6942: "Targeting CCNE1 Amplification in Gastric Cancer." On April 29, this poster examines the role of CCNE1 amplification in gastric cancer and potential therapeutic strategies. Obsidian's cytoDRiVE® platform allows for precise spatiotemporal control of protein functions using FDA-approved small molecules. Thistechnology is expected to broaden the application of cell and gene therapies. Founded in 2016, Obsidian Therapeutics is based in Cambridge, Massachusetts, and Montreal, Canada. The company's focus on advanced engineered cell and gene therapies aligns with its mission to deliver transformative treatments for challenging diseases like cancer. Industry insiders laud Obsidian’s work, particularly its ability to enhance T cell responses and reduce exhaustion through precise cytokine regulation. With ongoing preclinical and early clinical research showing promising results, Obsidian is poised to become a key player in cancer treatment innovation. Industry Reactions and Company Profiles Industry experts widely agree that the early data being presented by Incyte, Talus Bio, Repare Therapeutics, and Obsidian Therapeutics at the 2025 AACR are highly encouraging. Each company brings a unique approach and set of technologies to the table, contributing to the advancement of precision oncology and personalized cancer treatments. Incyte: Known for its global presence and robust drug pipeline, Incyte continues to push boundaries in cancer and MDS research. The company’s early projects, including INCB177054 and INCA33890, are seen as potentially game-changing therapies. Talus Bio: Talus’s innovative platform for targeting transcription factors could redefine the treatment of refractory cancers, with its high-throughput analysis and AI-driven discovery processes setting it apart in the biotech landscape. Repare Therapeutics: With its focus on synthetic lethality and gene-specific targets, Repare is making significant strides in precision oncology. The company’s SNIPRx® platform and ongoing clinical trials demonstrate its commitment to addressing unmet medical needs in cancer patients. NextPoint Therapeutics: NextPoint’s advancement in ADC technology and B7-H7-targeted therapies offers a fresh perspective on treating solid tumors. The company’s precision approach and robust preclinical data are viewed favorably for their potential to improve patient outcomes. Obsidian Therapeutics: Obsidian’s cytoDRiVE® technology, which allows for precise cytokine regulation, is seen as a crucial development in enhancing the safety and efficacy of cancer treatments. The company’s multi-center trial and preclinical data support its growing presence in the field. These companies collectively represent a formidable force in cancer research, each bringing cutting-edge science and innovative approaches to the table. Their presentations at AACR 2025 will likely spark further interest and collaboration within the industry, potentially leading to new breakthroughs in cancer care.